Sartorius AG

1SRT3

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    13,878

Stocks News & Analysis

stocks

Are declining Chinese births a red flag for A2 Milk?

Demographic challenges in A2’s largest market lead to sell-off.
stocks

Is this ASX share a value trap or bargain?

Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,108.6016.200.18%
CAC 408,030.6531.93-0.40%
DAX 4024,406.80296.32-1.20%
Dow JONES (US)48,488.59870.74-1.76%
FTSE 10010,112.5414.24-0.14%
HKSE26,585.0697.550.37%
NASDAQ22,954.32561.07-2.39%
Nikkei 22552,774.64216.46-0.41%
NZX 50 Index13,417.17156.76-1.15%
S&P 5006,796.86143.15-2.06%
S&P/ASX 2008,782.9014.000.16%
SSE Composite Index4,116.943.290.08%

Market Movers